TrialThe Journal of clinical investigation2021

CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.

Pablo Tebas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.